These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

478 related items for PubMed ID: 11354394

  • 21. Dorzolamide. A review of its pharmacology and therapeutic potential in the management of glaucoma and ocular hypertension.
    Balfour JA, Wilde MI.
    Drugs Aging; 1997 May; 10(5):384-403. PubMed ID: 9143858
    [Abstract] [Full Text] [Related]

  • 22. An eight-week, multicentric, randomized, interventional, open-label, phase 4, parallel comparison of the efficacy and tolerability of the fixed combination of timolol maleate 0.5%/brimonidine tartrate 0.2% versus fixed combination of timolol maleate 0.5%/dorzolamide 2% in patients with elevated intraocular pressure.
    Hatanaka M, Grigera DE, Barbosa WL, Jordao M, Susanna R.
    J Glaucoma; 2008 Dec; 17(8):674-9. PubMed ID: 19092465
    [Abstract] [Full Text] [Related]

  • 23. Comparison of brimonidine/latanoprost and timolol/dorzolamide: two randomized, double-masked, parallel clinical trials.
    Zabriskie N, Netland PA, Brimonidine with Latanoprost Study Groups 1 and 2.
    Adv Ther; 2003 Dec; 20(2):92-100. PubMed ID: 12836809
    [Abstract] [Full Text] [Related]

  • 24. Twice-daily brinzolamide/brimonidine fixed combination versus brinzolamide or brimonidine in open-angle glaucoma or ocular hypertension.
    Aung T, Laganovska G, Hernandez Paredes TJ, Branch JD, Tsorbatzoglou A, Goldberg I.
    Ophthalmology; 2014 Dec; 121(12):2348-55. PubMed ID: 25064721
    [Abstract] [Full Text] [Related]

  • 25. Comparison of the efficacy and safety of dorzolamide 2% when added to brimonidine 0.2% or timolol maleate 0.5% in patients with primary open-angle glaucoma.
    Oztürk F, Ermiş SS, Inan UU, Aşagidag A, Yaman S.
    J Ocul Pharmacol Ther; 2005 Feb; 21(1):68-74. PubMed ID: 15718830
    [Abstract] [Full Text] [Related]

  • 26. Effectiveness and safety of brimonidine as adjunctive therapy for patients with elevated intraocular pressure in a large, open-label community trial.
    Lee DA, Gornbein JA.
    J Glaucoma; 2001 Jun; 10(3):220-6. PubMed ID: 11442187
    [Abstract] [Full Text] [Related]

  • 27. Twelve-month results of an ongoing randomized trial comparing brimonidine tartrate 0.2% and timolol 0.5% given twice daily in patients with glaucoma or ocular hypertension. Brimonidine Study Group 2.
    LeBlanc RP.
    Ophthalmology; 1998 Oct; 105(10):1960-7. PubMed ID: 9787370
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. The efficacy of dorzolamide, a topical carbonic anhydrase inhibitor, in combination with timolol in the treatment of patients with open-angle glaucoma and ocular hypertension.
    Hartenbaum D.
    Clin Ther; 1996 Oct; 18(3):460-5. PubMed ID: 8829021
    [Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. The efficacy and safety of the dorzolamide-timolol combination versus the concomitant administration of its components. Dorzolamide-Timolol Study Group.
    Strohmaier K, Snyder E, DuBiner H, Adamsons I.
    Ophthalmology; 1998 Oct; 105(10):1936-44. PubMed ID: 9787367
    [Abstract] [Full Text] [Related]

  • 36. Clinical success and quality of life with brimonidine 0.2% or timolol 0.5% used twice daily in glaucoma or ocular t hypertension: a randomized clinical trial. Brimonidine Outcomes Study Group I.
    Javitt JC, Schiffman RM.
    J Glaucoma; 2000 Jun; 9(3):224-34. PubMed ID: 10877373
    [Abstract] [Full Text] [Related]

  • 37. Clinical experience with brimonidine 0.2% and timolol 0.5% in glaucoma and ocular hypertension.
    Schuman JS.
    Surv Ophthalmol; 1996 Nov; 41 Suppl 1():S27-37. PubMed ID: 8970247
    [Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39. Twice-daily 0.2% brimonidine-0.5% timolol fixed-combination therapy vs monotherapy with timolol or brimonidine in patients with glaucoma or ocular hypertension: a 12-month randomized trial.
    Sherwood MB, Craven ER, Chou C, DuBiner HB, Batoosingh AL, Schiffman RM, Whitcup SM.
    Arch Ophthalmol; 2006 Sep; 124(9):1230-8. PubMed ID: 16966616
    [Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 24.